GlassScriptPhysician profile
Maylin Paez
NPI 1093378622
$1,156.69
in general payments reported to CMS, 2019-2025
14 companies · $10.28 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $326 · 2023: $576 · 2024: $244 · 2025: $10.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.97 | 2023 | Farxiga |
| Phathom Pharmaceuticals, INC. | $135.27 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $124.99 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.37 | 2022 | |
| Abbvie INC. | $122.93 | 2023 | |
| Sanofi-Aventis U.S. LLC | $81.18 | 2024 | |
| Biogen, INC. | $43.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.69 | 2022 | |
| Pfizer INC. | $30.90 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $27.34 | 2023 | Rexulti |
| Boston Scientific Corporation | $23.10 | 2024 | Watchman Flx |
| Novo Nordisk INC | $20.05 | 2023 | Rybelsus |
| Amgen INC. | $14.79 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maylin Paez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.